<DOC>
	<DOC>NCT02202213</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).</brief_summary>
	<brief_title>Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Man or woman aged ≥18 years and ≤60 years with a body mass index (BMI) of ≥18.5 and ≤38 m2 Primary diagnosis of schizophrenia according to DSMIVTR™ (codes 295.10, 295.20, 295.30, 295.90) Clinical Global Impression Severity of Illness (CGIS) score ≤4 (moderately ill) at the Screening Visit and Baseline Visit (Day 1) PANSS total score ≤80 at the Screening Visit and the Baseline Visit (Day 1) Score of 4 (moderate) of the following PANSS items at the Screening Visit and the Baseline Visit (Day 1): P7 (hostility), G8 (uncooperativeness) Minimal level of extrapyramidal signs, defined as a score ≤5 (moderately severe) in any of the four Clinical Global Impression of Severity (CGIS) items of the ESRSA; parkinsonism, akathisia, dystonia, and tardive dyskinesia at the Screening Visit and the Baseline Visit Willingness to be hospitalised for approximately 3 weeks after the Baseline Visit (Day 1) The patient experienced an acute exacerbation requiring hospitalization within the last 6 months The patient experienced an acute exacerbation requiring increase in antipsychotic medication (with reference to drug or dose) within the last 4 weeks Other predefined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>